Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
Status:
Not yet recruiting
Trial end date:
2027-07-16
Target enrollment:
Participant gender:
Summary
To learn if the combination of nivolumab and relatlimab can help to control renal medullary
carcinoma (RMC) that is locally advanced or metastatic (has spread).